PALO ALTO, Calif., July 18 /PRNewswire/ -- The introduction of the oral antiplatelet drug Plavix in 1998 by Bristol-Myers Squibb and Sanofi-Aventis revolutionized the antiplatelet market in the United States, boosting it to multi-billion dollar status. In 2005, this blockbuster drug registered $3,235.0 million in sales and has been responsible for much of the market’s overall growth since its introduction. Today, Plavix is the leader in branded oral antiplatelet therapy.
“Growth in the oral antiplatelet sector is likely to continue expansion of the upside of the market,” notes Frost & Sullivan Research Analyst Daniel Ruppar. “With injectable product revenues hampered by growth issues in the Glycoprotein IIb/IIIa inhibitors, oral products are likely to be the primary source of market growth throughout the forecast period.”
New analysis from Frost & Sullivan (http://www.pharma.frost.com ), U.S. Antiplatelet Market, finds that this market earned revenues of $3.85 billion in 2005 and is likely to reach $5.49 billion in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Antiplatelet Market, then send an e-mail to Melina Trevino, Corporate Communications, at melina.trevino@frost.com with your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information by email upon receipt of the above information.
Rising cost concerns in the current healthcare environment are influencing product choice considerably, thereby reducing the ability of many acute care drugs to maintain expansive revenue growth. Combined with competing trial data from other therapy areas, these cost pressures have had a further negative impact on revenues in the injectable antiplatelet sector.
At the same time, the impending patent protection loss for Plavix has created an urgent need for new products in order to sustain branded revenues in the market. Companies need to develop pipeline technologies on an ongoing basis to refine existing antiplatelet therapy and create new treatment options for physicians, both in the acute hospital environment as well as for outpatient treatment.
Product innovation that can result in greater control over platelet function could open up fresh revenue sources as well as expand treatment options in hospitals. Advances in these areas could also widen the scope of antiplatelet products in new areas such as cardiac surgery.
At present, there is a strong opportunity for novel oral products to enter the market - as not every patient is served by those currently available, including aspirin. Around 15-50 percent of patients are believed to be aspirin resistant, while approximately 28 percent of patients using Plavix do not respond to treatment.
“Continued product innovation is likely to result in the clinical development of products that have the potential to improve upon currently used therapies in both the inpatient and outpatient areas,” remarks Ruppar. “This in turn can result in improved outcomes and increase patients’ quality of life as well as generate new revenue sources for the future.”
U.S. Antiplatelet Market, part of the Pharmaceuticals & Biotechnology Subscription, also includes research in the following markets: U.S. Intranasal Drug Delivery Market, U.S. Anticoagulant Market, and Emerging Therapeutics in the U.S. Colorectal Cancer Markets. All research included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com .
U.S. Antiplatelet Market F804 Contact: Melina Trevino Corporate Communications - North America P: 210.247.2440 F: 210.348.1003 E: melina.trevino@frost.com Radhika Menon Theodore Corporate Communications - Europe P: +91 (044) 42044541 E: rmtheodore@frost.com Jasminder Kaur Corporate Communications - Asia Pacific P: 65.6890.0937 F: 65.6890.0988 E: jkaur@frost.com Surbhi Dedhia Corporate Communications - India P: +91 22 2832 4705 Ext: 131 E: sdedhia@frost.com Sharmin Jassal Corporate Communications - Australia P: +61 2 8247 8900 F: +61 2 9252 8066 E: sharmin.jassal@frost.comhttp://www.frost.com
Keywords in this press release: antiplatelets, U.S., pipeline, Plavix, aspirin, oral therapy, oral antiplatelets, injectable antiplatelets, Glycoprotein IIb/IIIa inhibitors, patent protection, research, information, market, trends, technology, service, forecast, market share
Frost & Sullivan
CONTACT: Melina Trevino, Corporate Communications - North America,+1-210-247-2440, or fax, +1-210-348-1003, or melina.trevino@frost.com , orRadhika Menon Theodore, Corporate Communications - Europe,+91-044-42044541, or rmtheodore@frost.com , or Jasminder Kaur, CorporateCommunications - Asia Pacific, +65-6890-0937, or fax, +65-6890-0988, orjkaur@frost.com , or Surbhi Dedhia, Corporate Communications - India,+91-22-2832-4705 ext. 131, or sdedhia@frost.com , or Sharmin Jassal,Corporate Communications - Australia, +61-2-8247-8900, or fax,+61-2-9252-8066, or sharmin.jassal@frost.com , all of Frost & Sullivan
